胰头十二指肠切除术联合替吉奥治疗胰腺癌的临床观察
| 作者: |
1李洪波,
2刘崇忠
1 山东肥城矿业中心医院 普通外科，山东 肥城 271608 2 山东大学齐鲁医院 普通外科，山东 济南 250012 |
| 通讯: |
刘崇忠
Email: lczk1980@163.com |
| DOI: | 10.3978/.10.3978/j.issn.1005-6947.2015.09.005 |
摘要
目的：探讨胰头十二指肠切除术联合替吉奥治疗胰腺癌的疗效。
方法：2008年2月—2011年6月间，58例I~II期胰腺癌患者行胰头十二指肠切除术后分别采取替吉奥
（32例，观察组）和吉西他滨（26例，对照组）辅助化疗，比较两组患者的近、远期疗效及化疗期间不良反应的发生情况。
结果：两组患者化疗后血清中各肿瘤标志物水平均明显较化疗前下降（均P<0.05），但两组间差异无统计学意义（均P>0.05）；观察组患者总有效率明显高于对照组患者（37.50% vs. 30.77%，P<0.05）；生存分析显示，观察组患者1、1.5、2年的总生存率明显高于对照组患者（均P<0.05）；两组患者化疗期间不良反应均为I、II度，两组间不良反应发生率差异无统计学意义（P>0.05）。
结论：胰头十二指肠切除术加术后替吉奥辅助化疗治疗胰腺癌疗效确切，可有效延长患者术后生存期，且不良反应较轻，患者耐受良好。
关键词：
胰腺肿瘤；胰十二指肠切除术；放化疗，辅助；治疗结果
方法：2008年2月—2011年6月间，58例I~II期胰腺癌患者行胰头十二指肠切除术后分别采取替吉奥
（32例，观察组）和吉西他滨（26例，对照组）辅助化疗，比较两组患者的近、远期疗效及化疗期间不良反应的发生情况。
结果：两组患者化疗后血清中各肿瘤标志物水平均明显较化疗前下降（均P<0.05），但两组间差异无统计学意义（均P>0.05）；观察组患者总有效率明显高于对照组患者（37.50% vs. 30.77%，P<0.05）；生存分析显示，观察组患者1、1.5、2年的总生存率明显高于对照组患者（均P<0.05）；两组患者化疗期间不良反应均为I、II度，两组间不良反应发生率差异无统计学意义（P>0.05）。
结论：胰头十二指肠切除术加术后替吉奥辅助化疗治疗胰腺癌疗效确切，可有效延长患者术后生存期，且不良反应较轻，患者耐受良好。
Clinical observation of pancreaticoduodenectomy combined with tegafur/gimeracil/oteracil (S-1) adjuvant chemotherapy for pancreatic cancer
CorrespondingAuthor:LIU Chongzhou Email: lczk1980@163.com
Abstract
Objective: To assess the efficacy of pancreaticoduodenectomy (PD) followed by tegafur/gimeracil/oteracil (S-1) adjuvant chemotherapy in treatment of pancreatic cancer.
Methods: Between February 2008 and June 2011, 58 patients with stage I-II pancreatic cancer underwent PD followed by postoperative adjuvant chemotherapy with S-1 (32 cases, observational group) or gemcitabine (26 cases, control group). The short- and long- term efficacies as well as the incidence of adverse events during chemotherapy between the two groups of patients were compared.
Results: The levels of serum tumor markers in both groups of patients were significantly decreased after chemotherapy compared with their levels before chemotherapy (all P<0.05), but showed no significant difference between the two groups (all P>0.05); the overall response rate in observational group was significantly higher than that in control group (37.50% vs. 30.77%, P<0.05); survival analysis showed that the 1-, 1.5- and 2-year overall survival rate in observational group were significantly higher than those in control group (all P<0.05); the adverse reactions in either group were grade I or II, and there was no significant difference in incidence of adverse reactions between the two groups (P>0.05).
Conclusion: PD plus postoperative S-1 adjuvant chemotherapy for pancreatic cancer patients has proven efficacy, which may effectively prolong the postoperative survival time of the patients, with only mild adverse effects, and good tolerance.
Keywords：
Methods: Between February 2008 and June 2011, 58 patients with stage I-II pancreatic cancer underwent PD followed by postoperative adjuvant chemotherapy with S-1 (32 cases, observational group) or gemcitabine (26 cases, control group). The short- and long- term efficacies as well as the incidence of adverse events during chemotherapy between the two groups of patients were compared.
Results: The levels of serum tumor markers in both groups of patients were significantly decreased after chemotherapy compared with their levels before chemotherapy (all P<0.05), but showed no significant difference between the two groups (all P>0.05); the overall response rate in observational group was significantly higher than that in control group (37.50% vs. 30.77%, P<0.05); survival analysis showed that the 1-, 1.5- and 2-year overall survival rate in observational group were significantly higher than those in control group (all P<0.05); the adverse reactions in either group were grade I or II, and there was no significant difference in incidence of adverse reactions between the two groups (P>0.05).
Conclusion: PD plus postoperative S-1 adjuvant chemotherapy for pancreatic cancer patients has proven efficacy, which may effectively prolong the postoperative survival time of the patients, with only mild adverse effects, and good tolerance.